An ischemia-homing bioengineered nano-scavenger for specifically alleviating multiple pathogeneses in ischemic stroke

Duan, Ranran; Sun, Ke; Fang, Fang; Wang, Ning; He, Ruya; Gao, Yang; Jing, Lijun; Li, Yanfei; Gong, Zhe; Yao, Yaobing; Luan, Tingting; Zhang, Chaopeng; Zhang, Jinwei; Zhao, Yi; Xie, Haojie; Zhou, Yongyan; Teng, Junfang; Zhang, Jinfeng; Jia, Yanjie

doi:10.1186/s12951-022-01602-7

Cited by 10 publications

(9 citation statements)

References 59 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cerebrovascular diseases are common in neurology and are global public health issues. 16 According to the latest statistics, cerebrovascular diseases have ranked first in the death cause spectrum of urban and rural residents in China 17 and second around the world. 18 In recent years, the widely used neuroelectrophysiological techniques, such as SSR, Somatosensory evoked potential (SEP), and Motor evoked potential (MEP), can sensitively display brain dysfunctions as well as small or subclinical lesions that cannot be found by imaging examinations.…”

Section: Discussionmentioning

confidence: 99%

A Preliminary Study on Sympathetic Skin Response in Acute Ischemic Cerebrovascular Disease

Chen¹,

Chen²,

Ye³

et al. 2023

IJGM

View full text Add to dashboard Cite

Purpose The study aims to identify the characteristics of SSR in patients with AICVD and their correlation with clinical presentations. Methods SSR of the upper limbs, the National Institute of Health stroke scale (NIHSS), the Barthel index (BI), the Essen stroke risk score (ESRS), and imaging examinations, was evaluated in 30 healthy subjects and 66 patients with AICVD. All results were recorded and analyzed via Statistical Package for the Social Sciences (SPSS 22.0) software. t -test and Spearman rank correlation were used. Results Compared to the control group, SSR of upper limbs in patients with AICVD showed prolonged latency, reduced amplitude, and disappeared waveform ( p=0.000, p=0.015, p=0.004 ), No statistically significant difference was observed between the affected side and the healthy side ( p=0.068, p=0.661 ). In the case group, the higher the abnormal rate of SSR, the more severe the neurological impairment (NIHSS and ADL scores) and the worse the long-term prognosis. Specific results are as follows: Firstly, the total abnormality rate of SSR, prolonged SSR latency were positively related to the NIHSS, also the ESRS ( r=0.347, p=0.004; r=0.437, p<0.001 ), ( r=0.371, p=0.005; r=0.433, p=0.001 ), the reduced amplitude was positively related to the NIHSS ( r=0.341, p=0.012 ) while the disappeared waveform was positively related to the ESRS ( r=0.299, p=0.015 ); Secondly, the total abnormality rate of SSR, prolonged SSR latency and reduced amplitude were negatively related to the BI ( r=−0.346, p=0.004 ) ( r=−0.426, p=0.001) ( r=−0.316, p=0.020 ). Conclusion There may be inhibition of sympathetic reflex activity in patients with AICVD, SSR abnormality rate in patients with AICVD may be correlated with the degree of neurological impairment and long-term prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

A Preliminary Study on Sympathetic Skin Response in Acute Ischemic Cerebrovascular Disease

Chen¹,

Chen²,

Ye³

et al. 2023

IJGM

View full text Add to dashboard Cite

show abstract

“…A new trend for microglia immunomodulation involves the functionalization of NPs through microglia components, as reported by Duan et al. [ 270 ] in the context of ischemic stroke treatment ( Figure ). They designed a nano‐scavenger composed of a self‐assembled core containing tannic acid (TA) and the enzyme CAT with a cell membrane coating derived from M2‐polarized microglia.…”

Section: Nanostructures For M2 Activation Of Microglia/macrophagesmentioning

confidence: 92%

“…Reproduced with permission. [270] M2 phenotype at both mRNA and protein levels, suppressing pro-inflammatory responses and exhibiting a neuroprotective effect. [274] Promising results about the use of AuNCs have also been observed in treating SCI in combination with berberine, a natural anti-inflammatory quaternary ammonium alkaloid isolated Coptidis rhizoma, demonstrating neuronal apoptosis alleviation by promoting M2 polarization.…”

Section: Inorganic Nanostructuresmentioning

confidence: 99%

See 1 more Smart Citation

Nanomaterials as Microglia Modulators in the Treatment of Central Nervous System Disorders

Battaglini,

Marino,

Montorsi

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Microglia play a pivotal role in the central nervous system (CNS) homeostasis, acting as housekeepers and defenders of the surrounding environment. These cells can elicit their functions by shifting into two main phenotypes: pro‐inflammatory classical phenotype, M1, and anti‐inflammatory alternative phenotype, M2. Despite their pivotal role in CNS homeostasis, microglia phenotypes can influence the development and progression of several CNS disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, ischemic stroke, traumatic brain injuries, and even brain cancer. It is thus clear as the possibility of modulating microglia activation has gained attention as a therapeutic tool against many CNS pathologies. Nanomaterials are an unprecedented tool for manipulating microglia responses, in particular to specifically target microglia and elicit an in situ immunomodulation activity. In this review we will focus our discussion on two main aspects: we will analyze the possibility of using nanomaterials to stimulate a pro‐inflammatory response of microglia against brain cancer and we will introduce nanostructures able to foster an anti‐inflammatory response for treating neurodegenerative disorders. The final aim is to stimulate the analysis of the development of new microglia nano‐immunomodulators, paving the way for innovative and effective therapeutic approaches for the treatment of CNS disorders.This article is protected by copyright. All rights reserved

show abstract

“…[94] In recent years, nanotherapeutics, utilizing nanotechnology to alter the pharmacology of drugs and therapies, show great potential in revolutionizing the treatment of many diseases including IBD and other inflammatory diseases owing to their advantages such as targeted drug delivery, improved drug solubility, extended drug half-life, and reduced drug immunogenicity. [95][96][97][98][99][100] In particular, small-molecule drugs with intrinsic antioxidant and anti-inflammatory effects are the first choice to alleviate oxidative stress in IBD. However, the poor water solubility greatly limits their clinical applications.…”

Section: Ibd Nanotherapeutics Based On Depletion Of Excessive Rosmentioning

confidence: 99%

Advanced Nanomedicine: Redefining Therapeutic Paradigms for Inflammatory Bowel Disease

Zhang

Wang

Sun

et al. 2023

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD), a chronic and recurrent gastrointestinal inflammatory disorder with a variety of painful clinical manifestations and an increased risk of cancerization or death, has become an emerging challenge to global healthcare due to its rapidly increasing incidence. At present, there is no efficient cure against IBD because of the elusive etiology and pathogenesis of IBD. Therefore, the development of alternative therapeutic strategies with positive clinical efficacy and reduced side effects is urgently needed. In recent years, the great prosperity of nanomedicine promoted by a variety of advanced nanomaterials is redefining more attractive and promising therapeutic strategies for IBD owing to their advantages in the physiological stability, bioavailability, and targeting of inflammatory sites. In this review, firstly the basic characteristics of healthy and inflammatory intestinal microenvironments are presented. Then, different administration routes and targeting strategies of nanotherapeutics for IBD treatment are reviewed. Subsequently, a specific focus is placed on the introduction of nanotherapeutic treatments based on different IBD pathogenesis. Finally, some future challenges and perspectives of the currently developed nanomedicines for IBD treatment are provided. It is believed that the above topics will attract researchers from various fields including medicine, biological sciences, materials, chemistry and pharmaceutics.

show abstract

An ischemia-homing bioengineered nano-scavenger for specifically alleviating multiple pathogeneses in ischemic stroke

Cited by 10 publications

References 59 publications

A Preliminary Study on Sympathetic Skin Response in Acute Ischemic Cerebrovascular Disease

A Preliminary Study on Sympathetic Skin Response in Acute Ischemic Cerebrovascular Disease

Nanomaterials as Microglia Modulators in the Treatment of Central Nervous System Disorders

Advanced Nanomedicine: Redefining Therapeutic Paradigms for Inflammatory Bowel Disease

Contact Info

Product

Resources

About